top of page

Advancing Breakthroughs, Changing Lives

Bridging the Gap from Discovery to Therapy Through Patient-Centric Investing

Who We Are

Advancing Innovation Through Strategic Investment and Scientific Excellence

Our Mission

Investing with Broad Scope for High Patient Impact

As Dana-Farber Cancer Institute’s venture fund, we invest in innovative companies by leveraging technologies or expertise from the Institute. Although our main focus is oncology therapeutics and diagnostics, we pursue opportunities across a variety of disease areas and sectors to maximize patient impact.

Photo _ Sam Ogden _ Dana-Farber

 Photo @ Sam Ogden / Dana-Farber

What Makes Us Unique

Grounded in Excellence, Guided by Innovation

Founded in 2021, Binney Street Capital was established to build on Dana-Farber’s legacy of scientific breakthroughs and compassionate care. We leverage the expertise of top tier researchers, clinicians, and business partners to identify and bridge transformative ideas from discovery to clinical validation. 

Photo _ Sam Ogden _ Dana-Farber

 Photo @ Sam Ogden / Dana-Farber

Our Investment Strategy

Breakthrough Science with Transformative Potential

We invest across the innovation life cycle from company creation through early clinical validation. We conduct a rigorous evaluation process and invest in the most promising patient-centric ideas and teams that best balance biological, technical, and translational risks.

Photo _ Sam Ogden _ Dana-Farber

 Photo @ Sam Ogden / Dana-Farber

Value Add for Portfolio Companies

Building Success, Together

We are dedicated to being a long-term strategic partner at every stage and positioning our portfolio companies for success. In addition to capital, we support our portfolio companies with clinical expertise, insights from cutting edge research, and resources available in Boston and beyond.

Photo _ Sam Ogden _ Dana-Farber

 Photo @ Sam Ogden / Dana-Farber

Companies Driving Change

Our portfolio companies span a range of healthcare industries and technologies across multiple disease areas

Artboard 1 copy 7-100.jpg

Matchpoint is discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.  

Artboard 1 copy 6-100.jpg

NextPoint is unlocking the potential of B7-H7 for precision oncology therapeutics.

Artboard 1 copy 8-100.jpg

Precede is expanding the reach of precision medicine by providing unprecedented resolution into disease-defining biology from a blood test.

predicta-card.jpg

Predicta Biosciences is transforming patient care with molecular diagnostics that guide precision medicine for blood cancers and autoimmune diseases.

neomorph-logo.png

Neomorph is pioneering molecular glue medicines to target and eliminate disease-causing proteins once thought impossible to treat.

Featured News

Key Updates from Binney Street Capital and our Portfolio Companies

Precede Bio
Precede launches Precede Bio Insight, a Genome-Wide Liquid Biopsy for Functional Tumor Biology
Predicta Bio
Predicta Biosciences appoints Dr. Craig L. Tendler as Independent Director to its Board
Matchpoint Tx
Matchpoint Announces Agreement with Novartis to Develop Oral Inhibitors for Inflammatory Disease
Nextpoint Tx
Nextpoint Announces Clinical Entry of NPX372 a First-In-Class B7-H7 Targeted T Cell Engager To Treat Solid Tumors
Neomorph
Neomorph Announces Closing of $100 Million in Series B Financing

What we do here,
changes lives everywhere.

To connect with Binney Street Capital,

please send an email to:

BinneyStreetCapital [at] DFCI.Harvard.edu

We use cookies and other tools to enhance your experience on our website and to analyze our web traffic. For more information about these cookies and the data collected, please refer to our Privacy Policy.

bottom of page